Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 10/2017

01-12-2017 | Original Article

Uptake of AV-1451 in meningiomas

Authors: Tyler J. Bruinsma, Derek R. Johnson, Ping Fang, Matthew Senjem, Keith A. Josephs, Jennifer L. Whitwell, Bradley F. Boeve, Mukesh K. Pandey, Kejal Kantarci, David T. Jones, Prashanthi Vemuri, Melissa Murray, Jonathan Graff-Radford, Christopher G. Schwarz, David S. Knopman, Ronald C. Petersen, Clifford R. Jack Jr., Val J. Lowe

Published in: Annals of Nuclear Medicine | Issue 10/2017

Login to get access

Abstract

Aim

AV-1451 is an imaging agent labeled with the positron-emitting radiolabel Fluorine-18. 18F-AV-1451 binds paired helical filament tau (PHF-tau), a pathology related to Alzheimer’s disease. In our study of AV-1451 uptake in the brains of cognitively normal subjects, we noted a case of a meningioma with visually significant uptake of AV-1451.

Objective

We initiated the present retrospective study to further examine cases of meningioma that underwent AV-1451 imaging.

Methods

We searched the patient records of 650 patients who had undergone AV-1451 at our institution for the keyword “meningioma” to identify potential cases. PET/CT and MRI results were visually reviewed and semi-quantitative analysis of PET was performed. A paired student’s t test was run between background and tumor standard uptake values. Fisher’s exact test was used to examine the association between AV-1451 uptake and presence of calcifications on CT.

Results

We identified 12 cases of meningioma, 58% (7/12) of which demonstrated uptake greater than background using both visual analysis and tumor-to-normal cortex ratios (T/N + 1.90 ± 0.83). The paired student’s t test revealed no statistically significant difference between background and tumor standard uptake values (p = 0.09); however, cases with a T/N ratio greater than one showed statistically higher uptake in tumor tissue (p = 0.01). A significant association was noted between AV-1451 uptake and presence of calcifications (p = 0.01).

Conclusion

AV-1451 PET imaging should be reviewed concurrently with anatomic imaging to prevent misleading interpretations of PHF-tau distribution due to meningiomas.
Literature
1.
Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement. 2013;9(6):666–76.CrossRefPubMed
2.
Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34(2):457–68.PubMed
3.
Villemagne VL, Okamura N. Tau imaging in the study of ageing, Alzheimer’s disease, and other neurodegenerative conditions. Curr Opin Neurobiol. 2016;36:43–51.CrossRefPubMed
4.
Scholl M, Lockhart SN, Schonhaut DR, O’Neil JP, Janabi M, Ossenkoppele R, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971–82.CrossRefPubMedPubMedCentral
5.
Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139(Pt 5):1551–67.CrossRefPubMedPubMedCentral
6.
Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14(1):114–24.CrossRefPubMed
7.
Dani M, Brooks DJ, Edison P. Tau imaging in neurodegenerative diseases. Eur J Nucl Med Mol Imaging. 2016;43(6):1139–50.CrossRefPubMed
8.
Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun. 2016;4(1):58.CrossRefPubMedPubMedCentral
9.
Marquie M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787–800.CrossRefPubMedPubMedCentral
10.
11.
Pamir MN, Black PM, Fahlbusch R. Meningiomas: a comprehensive text, vol xxiii. Philadelphia: Saunders/Elsevier; 2010. p. 773.
12.
13.
Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61(3):215–25 (discussion 26–29).CrossRefPubMed
14.
Bondy M, Ligon BL. Epidemiology and etiology of intracranial meningiomas: a review. J Neurooncol. 1996;29(3):197–205.CrossRefPubMed
15.
Fogh SE, Johnson DR, Barker FG, Brastianos PK, Clarke JL, Kaufmann TJ, et al. Case-based review: meningioma. Neuro Oncol Pract. 2016;3(2):120–34.CrossRef
16.
Sheporaitis LA, Osborn AG, Smirniotopoulos JG, Clunie DA, Howieson J, D’Agostino AN. Intracranial meningioma. AJNR Am J Neuroradiol. 1992;13(1):29–37.PubMed
17.
Di Chiro G, Hatazawa J, Katz DA, Rizzoli HV, De Michele DJ. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology. 1987;164(2):521–6.CrossRefPubMed
18.
Lee JW, Kang KW, Park SH, Lee SM, Paeng JC, Chung JK, et al. 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. Eur J Nucl Med Mol Imaging. 2009;36(10):1574–82.CrossRefPubMed
19.
Rachinger W, Stoecklein VM, Terpolilli NA, Haug AR, Ertl L, Poschl J, et al. Increased 68 Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med. 2015;56(3):347–53.CrossRefPubMed
20.
Chung JK, Kim YK, Kim SK, Lee YJ, Paek S, Yeo JS, et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002;29(2):176–82.CrossRefPubMed
21.
Tripathi M, Sharma R, Varshney R, Jaimini A, Jain J, Souza MM, et al. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med. 2012;37(2):158–63.CrossRefPubMed
22.
Grosu AL, Weber WA, Astner ST, Adam M, Krause BJ, Schwaiger M, et al. 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66(2):339–44.CrossRefPubMed
23.
Nyberg G, Bergstrom M, Enblad P, Lilja A, Muhr C, Langstrom B. PET-methionine of skull base neuromas and meningiomas. Acta Otolaryngol. 1997;117(4):482–9.CrossRefPubMed
24.
Aki T, Nakayama N, Yonezawa S, Takenaka S, Miwa K, Asano Y, et al. Evaluation of brain tumors using dynamic 11C-methionine-PET. J Neurooncol. 2012;109(1):115–22.CrossRefPubMed
25.
Lau EW, Drummond KJ, Ware RE, Drummond E, Hogg A, Ryan G, et al. Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. J Clin Neurosci. 2010;17(1):43–9.CrossRefPubMed
26.
Pruim J, Willemsen AT, Molenaar WM, van Waarde A, Paans AM, Heesters MA, et al. Brain tumors: L-[1-C-11]tyrosine PET for visualization and quantification of protein synthesis rate. Radiology. 1995;197(1):221–6.CrossRefPubMed
27.
Rutten I, Cabay JE, Withofs N, Lemaire C, Aerts J, Baart V, et al. PET/CT of skull base meningiomas using 2-18F-fluoro-L-tyrosine: initial report. J Nucl Med. 2007;48(5):720–5.CrossRefPubMed
28.
Moresco RM, Scheithauer BW, Lucignani G, Lombardi D, Rocca A, Losa M, et al. Oestrogen receptors in meningiomas: a correlative PET and immunohistochemical study. Nucl Med Commun. 1997;18(7):606–15.CrossRefPubMed
29.
Fujimoto M, Yoshino E, Hirakawa K, Fujimoto J, Tamaya T. Estrogen receptors in brain tumors. Clin Neuropharmacol. 1984;7(4):357–62.CrossRefPubMed
30.
Nathoo F, Dean CB. A mixed mover-stayer model for spatiotemporal two-state processes. Biometrics. 2007;63(3):881–91.CrossRefPubMed
31.
Meewes C, Bohuslavizki KH, Krisch B, Held-Feindt J, Henze E, Clausen M. Molecular biologic and scintigraphic analyses of somatostatin receptor-negative meningiomas. J Nucl Med. 2001;42(9):1338–45.PubMed
32.
Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al. Characterization of 68 Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med. 2005;46(5):763–9.PubMed
33.
Gehler B, Paulsen F, Oksuz MO, Hauser TK, Eschmann SM, Bares R, et al. [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol. 2009;4:56.CrossRefPubMedPubMedCentral
34.
Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. 68 Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2008;35(1):72–9.CrossRefPubMed
35.
Nathoo N, Ugokwe K, Chang AS, Li L, Ross J, Suh JH, et al. The role of 111indium-octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas. J Neurooncol. 2007;81(2):167–74.CrossRefPubMed
36.
Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J, et al. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med. 2001;42(7):1053–6.PubMed
37.
Lowe VJ, Kemp BJ, Jack CR Jr, Senjem M, Weigand S, Shiung M, et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med. 2009;50(6):878–86.CrossRefPubMedPubMedCentral
38.
Miyazono M, Iwaki T, Kitamoto T, Shin RW, Fukui M, Tateishi J. Widespread distribution of tau in the astrocytic elements of glial tumors. Acta Neuropathol. 1993;86(3):236–41.CrossRefPubMed
39.
Yamamoto Y, Maeda Y, Kawai N, Kudomi N, Nishiyama Y. Unexpected finding of cerebral meningioma on (11)C-PiB PET. Clin Nucl Med. 2013;38(4):292–3.CrossRefPubMed
40.
Kim HY, Kim J, Lee JH. Incidental finding of meningioma on C11-PIB PET. Clin Nucl Med. 2012;37(2):e36–7.CrossRef
Metadata
Title
Uptake of AV-1451 in meningiomas
Authors
Tyler J. Bruinsma
Derek R. Johnson
Ping Fang
Matthew Senjem
Keith A. Josephs
Jennifer L. Whitwell
Bradley F. Boeve
Mukesh K. Pandey
Kejal Kantarci
David T. Jones
Prashanthi Vemuri
Melissa Murray
Jonathan Graff-Radford
Christopher G. Schwarz
David S. Knopman
Ronald C. Petersen
Clifford R. Jack Jr.
Val J. Lowe
Publication date
01-12-2017
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 10/2017
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-017-1205-0

Other articles of this Issue 10/2017

Annals of Nuclear Medicine 10/2017 Go to the issue

Original Article

Assessment of intratumor heterogeneity in mesenchymal uterine tumor by an 18F-FDG PET/CT texture analysis

Original Article

Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors

Original Article

The effect of short-term treatment with lithium carbonate on the outcome of radioiodine therapy in patients with long-lasting Graves’ hyperthyroidism

Original Article

CT-based SPECT attenuation correction and assessment of infarct size: results from a cardiac phantom study

Original Article

Textural features and SUV-based variables assessed by dual time point 18F-FDG PET/CT in locally advanced breast cancer

Original Article

Inter- and intra-observer reproducibility of quantitative analysis for FP-CIT SPECT in patients with DLB